UBS analyst Matthew Weston downgraded Novartis (NVS) to Neutral from Buy with a price target of CHF 104, down from CHF 111. The firm believes the company’s key growth drivers are already reflected in consensus expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Could Moderna’s (MRNA) 65% Stock Plunge Entice a Takeover?
- Novartis initiated with an Underweight at Morgan Stanley
- Novartis agrees to acquire Anthos for up to $3.1B
- Hold Rating for Novartis AG Due to Limited Potential of Abelacimab Despite Acquisition of Anthos Therapeutics
- M&A News: Novartis Seals $3.1B Deal to Acquire Anthos